Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars
Executive Summary
Mylan's Kokino spoke with Scrip about what he called the successful launch of the company's first biosimilar in the US, a version of Amgen's Neulasta, the state of the US biosimilar market and resetting expectations.